Neulasta® (pegfilgrastim) Onpro® kit
Healthcare Provider INSTRUCTIONS FOR USE

Guide to Parts

Neulasta Prefilled Syringe

- Syringe barrel
- Plunger rod
- Label and expiration date
- Medicine
- Gray needle cap

On-body Injector for Neulasta

- Blue needle cover
- Automatic needle & cannula opening (under needle cover)
- Cannula window
- Pull tabs
- Fill indicator
- Status light
- Medicine port
- Adhesive backing
Important

READ THE FOLLOWING INSTRUCTIONS BEFORE USING NEULASTA ONPRO KIT

Prescribing Information
• See Prescribing Information for information on Neulasta.
• The on-body injector is for adult patients only.
• The on-body injector is not recommended for patients with Hematopoietic Subsyndrome of Acute Radiation Syndrome.
• Neulasta prefilled syringe gray needle cap contains dry natural rubber, which is derived from latex.
• For patients who have had severe skin reactions to acrylic adhesives, consider the benefit:risk profile before administering pegfilgrastim via the on-body injector for Neulasta.

Application Information
• The on-body injector should be applied to intact, non-irritated skin on the abdomen or back of the arm. The back of the arm may only be used if there is a caregiver available to monitor the status of the on-body injector.
• The on-body injector has a self-adhesive backing to attach it to the skin, do not use additional materials to hold it in place as this could dislodge the cannula and lead to a missed or incomplete dose of Neulasta.

Environmental Information
• Do not expose the on-body injector for Neulasta to the following environments as the on-body injector may be damaged and the patient could be injured:
  • Diagnostic imaging (e.g., CT Scan, MRI, Ultrasound, X-ray)
  • Radiation treatment
  • Oxygen rich environments such as hyperbaric chambers

Cautions
• Do not use Neulasta Onpro kit to deliver any other drug product
• Do not use the on-body injector if its packaging has been previously opened, or the expiration date on the carton or any components has passed.
• Do not use if the name Neulasta does not appear on Neulasta Onpro kit carton.
• Do not modify the on-body injector.
• Do not attempt to reapply the on-body injector.
• Do not use if either the on-body injector or prefilled syringe is dropped. Start again with a new kit.

Storage Information
• Store the kit in the refrigerator at 36°F to 46°F (2°C to 8°C) until ready for use. If the kit is stored at room temperature for more than 12 hours, do not use. Start again with a new kit.
• Keep the prefilled syringe in the kit carton until use to protect from light.
• Do not freeze the kit.
• Do not separate the components of Neulasta Onpro kit until ready for use.

For all questions, or if a patient calls you regarding any injector problems, call Amgen at 1-800-772-6436.
Step 1: Prepare

A  Place the syringe tray and the on-body injector tray on a clean, well-lit work surface.

Allow the syringe and on-body injector to come naturally to room temperature for 30 minutes prior to activating. Do not warm the kit components using a heat source.

B  Choose the patient’s injection site.

- Back of upper arm (triceps)
- Abdomen

Ask the patient about their ability to monitor and remove the on-body injector.

- Use the left or right side of the abdomen, except for a two-inch area right around navel.
- Use the back of upper arm only if there is a caregiver available to monitor the status of the on-body injector.
- Apply the on-body injector to intact, non-irritated skin.
- Do not apply the on-body injector on surgical sites or areas with scar tissue, moles, or excessive hair. In case of excessive hair, carefully trim hair to get the on-body injector close to the skin.
- Do not apply the on-body injector on areas where belts, waistbands, or tight clothing may rub against, disturb, or dislodge the on-body injector.
- Do not apply the on-body injector on areas where the on-body injector will be affected by folds in the skin.

C  Clean an area on the injection site larger than the on-body injector adhesive backing.

- Thoroughly clean the site with alcohol to enhance on-body adherence to the skin.
- Only use alcohol to clean the skin. Make sure the skin is oil-free prior to applying the on-body injector.
- Allow the skin to completely dry before attaching the on-body injector.
- Do not touch this area again before attaching the on-body injector.

Remove Neulasta prefilled syringe from tray.

D  For safety reasons:

- Do not grasp the gray needle cap.
- Do not grasp the plunger rod.
E  Inspect Neulasta prefilled syringe. Neulasta liquid should always be clear and colorless.

- Do not use if the liquid contains particulate matter or discoloration is observed prior to administration.
- Do not use the prefilled syringe if the expiration date has passed.
- Do not use if any part appears cracked or broken.
- Do not use if the gray needle cap is missing or not securely attached.
- Do not remove the gray needle cap until ready to fill the on-body injector.
- Do not shake the prefilled syringe.

In all the above cases, start again with a new kit.
Step 2: Fill

A  Remove air bubbles in prefilled syringe.

Injecting air bubbles could interfere with proper operation of the on-body injector.

• Remove the gray needle cap.
• Gently tap the syringe with your finger until air bubbles rise to the top.
• Slowly push air out of the syringe, taking care to not expel medicine.
• A small droplet at the tip of the needle during air purging is normal.
• Do not recap the syringe.

B  Center the needle directly over the medicine port and insert all the way into the port, avoiding sides.

Insert needle into medicine port at a 90 degree angle only.

• Do not remove the blue needle cover before filling the on-body injector.
• Do not insert the needle more than once.
• Do not bend the needle. Avoid spilling the medicine.
C  Push the plunger rod to empty entire syringe contents into the on-body injector.
   • During filling, you will hear beeping.
   • The status light will flash amber.
   • You now have 3 full minutes to apply the on-body injector to your patient.

Discard used syringe in sharps container.

D  Check to see if the on-body injector is full and the amber light is flashing. You should see a black line next to FULL on the fill indicator.

If this is not the case, do not use. Start again with a new Neulasta Onpro kit.

E  Firmly lift and remove the blue needle cover away from the on-body injector.
Step 3: Apply

A. Peel away both pull tabs to show the adhesive. Never touch hands or gloves to the adhesive.

Make sure skin is dry prior to applying the on-body injector.

- **Do not** pull off the adhesive pad or fold it.
- **Do not** touch or contaminate the automatic needle area.
- **Do not** use if the needle or cannula is extended past the adhesive or is extended before the on-body injector is placed on the patient.
- **Do not place adhesive on skin that is damp.**
B Before the cannula inserts, securely apply the on-body injector so it is visible and can be monitored by the patient or caregiver.

You now have time to carefully apply the on-body injector without folding or wrinkling the adhesive.

- **Do not** touch the adhesive.
- Grasp the on-body injector’s plastic case with your fingertips and only by sides, keeping fingers off of the adhesive.
- **Do not** let the adhesive bend or curl while applying the on-body injector to skin.
- **Important:** Once on the skin, **press firmly on the on-body injector** to ensure proper adhesion to the patient’s skin.
- Press around the entire adhesive so it lies down without folds or wrinkles.
- Hold the top of the on-body injector and run finger around the adhesive to create a secure attachment.
- If additional adhesion is deemed appropriate, an adhesive extender that fits around the on-body injector can be obtained by calling 1-844-MYNEULASTA (1-844-696-3852).
- **Do not** use other materials to secure the on-body injector to the patient that could cover audio/visual indicators or compress the on-body injector against the patient’s skin.
**Back of upper arm (triceps)**  
Vertical with the light facing down toward the elbow

**Abdomen**  
Horizontal with the light facing up and visible to the patient

**Do not worry if the on-body injector is quiet.**  
When 3 minutes are up, the on-body injector will beep telling you the cannula is about to insert.

**Step 4: Finish**

A **Wait for the status light to turn green.** This means the cannula has been inserted.

**Do not** remove the on-body injector during cannula insertion to avoid needle stick injury to you or to the patient.

**Check the quality of adhesion before sending the patient home.**

If the adhesive is wrinkled in front of the cannula window or has folds anywhere that prevent the on-body injector from securely adhering, remove the on-body injector. Start again with a new kit and call Amgen at 1-800-772-6436.
B Provide the Patient IFU Booklet for the patient to take home.

Fill in the Dose Delivery information on the booklet, and review the following instructions with your patient:

• The on-body injector will always flash a slow green light to let them know it is working properly.
• The patient should keep the on-body injector dry for at least 3 hours after it was placed on their skin.
• After approximately 27 hours, the dose delivery will begin. Dose delivery will take about 45 minutes, during this time, the on-body injector will flash a fast green light.
• When dose delivery is complete, the on-body injector will sound a long beep, and the status light will turn SOLID GREEN.
• Do not remove the on-body injector until the status light is SOLID GREEN.
• If the red error light is flashing, or the adhesive is noticeably wet (saturated), or the on-body injector is dislodged, the patient should contact their healthcare provider immediately as they may need a replacement dose.

Attention!

What to do if you hear beeping or when you look at status light and it is flashing red.
If at any time the on-body injector beeps continuously for 5 minutes, and the status light is flashing red, take the on-body injector off of the patient.

- **Do not** apply or leave the on-body injector on the patient if red error light is on.

In all cases, do not use. Start over with a new Neulasta Onpro kit, and call Amgen at 1-800-772-6436.

---

### What to do if your patient reports the status light is flashing red.

If the patient reports the status light is flashing red, they may not have received the full dose. Schedule a follow-up appointment with your patient.

### What to do if your patient reports the adhesive is saturated with fluid or the on-body injector is dripping.

[Image of saturated adhesive and dripping fluid]

If the patient reports an on-body injector leak, they may not have received the full dose. Schedule a follow-up appointment with your patient.

In all cases report the incident to Amgen at 1-800-772-6436.

---

Neulasta® (pegfilgrastim)

**Manufactured by:**
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, California 91320-1799
US License No. 1080

© 2002 to 2021 Amgen Inc. All rights reserved.
Before You Begin

The following is an overview of on-body injector preparation steps. Read this section first.

To prepare and apply the on-body injector, you will use a pre-filled syringe to fill and activate it.

As part of this process, the on-body injector uses lights and sounds as signals to help guide you through the preparation and application process.

As you fill the on-body injector, the status light flashes amber and the on-body injector beeps 3 times.

When the status light flashes amber and the on-body injector beeps, this means it has been properly filled and activated.

After the on-body injector activates, you will have 3 full minutes to remove the blue needle guard and adhesive backing, and then apply the on-body injector to your patient.

- The on-body injector will beep several times prior to inserting the cannula.
- Make sure you have the on-body injector properly secured to your patient before the cannula inserts.

When the status light flashes green, this means the on-body injector has successfully inserted the cannula.

For all questions, or if a patient calls you regarding any on-body injector problems, call Amgen at 1-800-772-6436.

Turn over to continue with the Instructions for Use.
<table>
<thead>
<tr>
<th>Symbol</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image1" alt="Symbol" /></td>
<td>Do not reuse this on-body injector. Single-use only</td>
</tr>
<tr>
<td><img src="image2" alt="Symbol" /></td>
<td>Refer to Instructions for Use</td>
</tr>
<tr>
<td><img src="image3" alt="Symbol" /></td>
<td>Do not use if packaging is damaged</td>
</tr>
<tr>
<td><img src="image4" alt="Symbol" /></td>
<td>Temperature limitation</td>
</tr>
<tr>
<td><img src="image5" alt="Symbol" /></td>
<td>Humidity limitation</td>
</tr>
<tr>
<td><img src="image6" alt="Symbol" /></td>
<td>Expiration date (use by date)</td>
</tr>
<tr>
<td><img src="image7" alt="Symbol" /></td>
<td>Reference/model number</td>
</tr>
<tr>
<td><img src="image8" alt="Symbol" /></td>
<td>Lot number</td>
</tr>
<tr>
<td><img src="image9" alt="Symbol" /></td>
<td>Type BF medical device (protection from electrical shock)</td>
</tr>
<tr>
<td><img src="image10" alt="Symbol" /></td>
<td>Sterilized by ethylene oxide</td>
</tr>
<tr>
<td><img src="image11" alt="Symbol" /></td>
<td>Waterproof up to 8 feet for 1 hour</td>
</tr>
<tr>
<td><img src="image12" alt="Symbol" /></td>
<td>Prescription use only</td>
</tr>
<tr>
<td><img src="image13" alt="Symbol" /></td>
<td>MR Unsafe</td>
</tr>
<tr>
<td><img src="image14" alt="Symbol" /></td>
<td>On-body injector for Neulasta® (pegfilgrastim)</td>
</tr>
<tr>
<td><img src="image15" alt="Symbol" /></td>
<td>Neulasta® (pegfilgrastim) prefilled syringe</td>
</tr>
<tr>
<td><img src="image16" alt="Symbol" /></td>
<td>Pressure Limitation</td>
</tr>
</tbody>
</table>

Do not expose the on-body injector for Neulasta to the following environments as the on-body injector may be damaged and the patient could be injured:
- Diagnostic imaging (e.g., CT Scan, MRI, Ultrasound, X-ray)
- Radiation treatment
- Oxygen rich environments such as hyperbaric chambers
Electromagnetic Compatibility
The information contained in this section (such as separation distances) is, in general, specifically written in regard to the on-body injector for Neulasta. The numbers provided will not guarantee faultless operation but should provide reasonable assurance of such. This information may not be applicable to other medical electrical equipment; older equipment may be particularly susceptible to interference.

General Notes:

Medical electrical equipment requires special precautions regarding electromagnetic compatibility (EMC), and needs to be installed and put into service according to the EMC information provided in this document.

Portable and mobile RF communications equipment can affect medical electrical equipment.

Cables and accessories not specified within the instructions for use are not authorized. Using cables and/or accessories may adversely impact safety, performance, and electromagnetic compatibility (increased emission and decreased immunity).

Care should be taken if the on-body injector for Neulasta is used adjacent to other electrical equipment; if adjacent use is inevitable, the on-body injector for Neulasta should be observed to verify normal operation in this setting.

<table>
<thead>
<tr>
<th>Electromagnetic Emissions</th>
<th>Compliance according to</th>
<th>Electromagnetic environment</th>
</tr>
</thead>
<tbody>
<tr>
<td>The on-body injector for Neulasta is intended for use in the electromagnetic environment specified below. The user of the on-body injector for Neulasta should ensure that it is used in such an environment.</td>
<td>RF Emissions (CISPR 11)</td>
<td>Group 1</td>
</tr>
<tr>
<td>CISPR B Emissions Classification</td>
<td>Class B</td>
<td></td>
</tr>
</tbody>
</table>


# Electromagnetic Immunity

The on-body injector for Neulasta is intended for use in the electromagnetic environment specified below. The user of this equipment should ensure that it is used in such an environment.

<table>
<thead>
<tr>
<th>Immunity Test</th>
<th>IEC 60601 Test Level</th>
<th>Compliance Level</th>
<th>Electromagnetic Environment-Guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>ESD</td>
<td>±8 kV Contact</td>
<td>±8 kV Contact</td>
<td>Floors should be wood, concrete or ceramic tile. If floors are synthetic, the r/h should be at least 30%.</td>
</tr>
<tr>
<td>IEC 61000-4-2</td>
<td>±15 kV Air</td>
<td>±15 kV Air</td>
<td></td>
</tr>
<tr>
<td>Power Frequency</td>
<td>30 A/m</td>
<td>30 A/m</td>
<td>Power frequency magnetic fields should be that of typical commercial or hospital environment.</td>
</tr>
<tr>
<td>50/60 Hz</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Magnetic Field IEC 61000-4-8</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Radiated RF Fields</td>
<td>3 V/m</td>
<td>(E1)=3 V/m</td>
<td>Portable and mobile communications equipment should be separated from the on-body injector for Neulasta by no less than the distances calculated/listed below: D=(3.5/V1)(√P) 150 kHz to 80 MHz D=(3.5/E1)(√P) 80 MHz to 800 MHz D=(7/E1)(√P) 800 MHz to 2.5 GHz Where P is the max power in watts and D is the recommended separation distance in meters. Field strengths from fixed transmitters, as determined by an electromagnetic site survey, should be less than the compliance levels (V1 and E1). Interference may occur in the vicinity of equipment containing a transmitter.</td>
</tr>
<tr>
<td>61000-4-3</td>
<td>80 MHz to 2.7 GHz</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Test specifications for ENCLOSURE PORT IMMUNITY to RF wireless communications equipment

The on-body injector for Neulasta is intended for use in the radio frequency environment specified below. The user of this equipment should ensure that it is used in such an environment.

<table>
<thead>
<tr>
<th>Test Frequency (MHz)</th>
<th>Band (MHz)</th>
<th>Service a)</th>
<th>Modulation b)</th>
<th>Maximum Power (W)</th>
<th>Distance (m)</th>
<th>Immunity Test Level (V/m)</th>
</tr>
</thead>
<tbody>
<tr>
<td>385</td>
<td>380-390</td>
<td>TETRA 400</td>
<td>Pulse modulation b) 18 Hz</td>
<td>1.8</td>
<td>0.3</td>
<td>27</td>
</tr>
<tr>
<td>450</td>
<td>430-470</td>
<td>GMRS 460, FRS 460</td>
<td>FM c) ± 5 kHz deviation 1 kHz sine</td>
<td>2</td>
<td>0.3</td>
<td>28</td>
</tr>
<tr>
<td>710</td>
<td>704-787</td>
<td>LTE Band 13, 17</td>
<td>Pulse modulation b) 217 Hz</td>
<td>0.2</td>
<td>0.3</td>
<td>9</td>
</tr>
<tr>
<td>745</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>780</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>810</td>
<td>800-960</td>
<td>GSM 800/900, TETRA 800, iDEN 820, CDMA 850, LTE Band 5</td>
<td>Pulse modulation b) 18 Hz</td>
<td>2</td>
<td>0.3</td>
<td>28</td>
</tr>
<tr>
<td>870</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>930</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1720</td>
<td>1700-1990</td>
<td>GSM 1800; CDMA 1900; GSM 1900; DECT; LTE Band 1, 3, 4, 25; UMTS</td>
<td>Pulse modulation b) 217 Hz</td>
<td>2</td>
<td>0.3</td>
<td>28</td>
</tr>
<tr>
<td>1845</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1970</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2450</td>
<td>2400-2570</td>
<td>Bluetooth, WLAN, 802.11 b/g/n, RFID 2450, LTE Band 7</td>
<td>Pulse modulation b) 217 Hz</td>
<td>2</td>
<td>0.3</td>
<td>28</td>
</tr>
<tr>
<td>5240</td>
<td>5100-5800</td>
<td>WLAN 802.11 a/n</td>
<td>Pulse modulation b) 217 Hz</td>
<td>0.2</td>
<td>0.3</td>
<td>9</td>
</tr>
<tr>
<td>5500</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5785</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**NOTE** If necessary to achieve the IMMUNITY TEST LEVEL, the distance between the transmitting antenna and the ME EQUIPMENT OF ME SYSTEM may be reduced to 1 m. The 1 m test distance is permitted by IEC 61000-4-3.
a) For some services, only the uplink frequencies are included.
b) The carrier shall be modulated using a 50% duty cycle square wave signal.
c) As an alternative to FM modulation, 50% pulse modulation at 18 Hz may be used because while it does not represent actual modulation, it would be worst case.

### Recommended separation distances between portable and mobile RF communications equipment and the on-body injector for Neulasta

You can help prevent electromagnetic interference by maintaining a minimum distance between portable and mobile RF communications equipment (transmitters) and the on-body injector for Neulasta, as recommended below, according to the maximum power of the communication equipment.

<table>
<thead>
<tr>
<th>Rated maximum output power of transmitter, in watts</th>
<th>Separation distance according to frequency of transmitter, in meters</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>150 kHz to 80 MHz [D=(3.5/V1)(\sqrt{P})]</td>
<td>80 MHz to 800 MHz [D=(3.5/E1)(\sqrt{P})]</td>
</tr>
<tr>
<td>0.01</td>
<td>0.11667</td>
<td>0.11667</td>
</tr>
<tr>
<td>0.1</td>
<td>0.36894</td>
<td>0.36894</td>
</tr>
<tr>
<td>1</td>
<td>1.1667</td>
<td>1.1667</td>
</tr>
<tr>
<td>10</td>
<td>3.6894</td>
<td>3.6894</td>
</tr>
<tr>
<td>100</td>
<td>11.667</td>
<td>11.667</td>
</tr>
</tbody>
</table>